quantisnow
FeedTopReportsPricing
⌘K
Live feed
10:48:02·66d
PRRelease
Acrivon Therapeutics Inc. logo
Erasca Inc. logo
Incyte Corp. logo
+2

Registration Momentum Builds Across the Oncology Pipeline

ACRV· Acrivon Therapeutics Inc.ERAS· Erasca Inc.INCY· Incyte Corp.KPTI· Karyopharm Therapeutics Inc.ONCY· Oncolytics Biotech Inc.
Health Care
Original source

Companies

  • ACRV
    Acrivon Therapeutics Inc.
    Health Care
  • ERAS
    Erasca Inc.
    Health Care
  • INCY
    Incyte Corp.
    Health Care
  • KPTI
    Karyopharm Therapeutics Inc.
    Health Care
  • ONCY
    Oncolytics Biotech Inc.
    Health Care

Recent analyst ratings

  • Mar 16INCYUpdateJefferies$94.00
  • Mar 10KPTIUpdateRodman & Renshaw$28.00
  • Feb 5KPTIUpdateCantor Fitzgerald-
  • Feb 5INCYUpdateH.C. Wainwright$135.00
  • Jan 27ERASUpdateMizuho$16.00
  • Jan 20INCYUpdateWells Fargo$107.00

Related

  • SEC19h
    Amendment: SEC Form SCHEDULE 13D/A filed by Acrivon Therapeutics Inc.
  • INSIDER19h
    Director Ra Capital Management, L.P. was granted 3,888,888 shares (SEC Form 4)
  • PR1d
    MINJUVI® (tafasitamab) for Relapsed or Refractory Follicular Lymphoma Approved in Australia
  • INSIDER1d
    SEC Form 4 filed by Rangwala Reshma
  • INSIDER2d
    SEC Form 4 filed by Miller Mary
  • INSIDER2d
    SEC Form 4 filed by Cagnoni Pablo J
  • PR3d
    Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Selected for Late-Breaking Oral Presentation at ASCO 2026 Annual Meeting
  • SEC3d
    Erasca Inc. filed SEC Form 8-K: Other Events
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022